HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Triapex Laboratories / Equity Capital Markets

<ul>
<li>Unlike traditional CROs which act as external service providers to handle scattered tasks, TRIAPEX is strategic R&amp;D partner for clients,offering end-to-end services covering entire process from drug discovery to NDA.</li>
<li>Monkeys, as biological assets, have their fair value changes directly recorded in profit statement, acting as an "amplifier" for TRIAPEX's performance. This will lead to significant fluctuations in future performance.</li>
<li>TRIAPEX's valuation would be lower than Joinn Lab. The final valuation depends on  the price trend of laboratory monkeys and the overall valuation of biopharmaceutical sector in Hong Kong stock market.</li>
</ul>


Unlike traditional CROs which act as external service providers to handle scattered tasks, TRIAPEX is strategic R&amp;D partner for clients,offering end-to-end services covering entire process from drug discovery to NDA.
Monkeys, as biological assets, have their fair value changes directly recorded in profit statement, acting as an "amplifier" for TRIAPEX's performance. This will lead to significant fluctuations in future performance.
TRIAPEX's valuation would be lower than Joinn Lab. The final valuation depends on  the price trend of laboratory monkeys and the overall valuation of biopharmaceutical sector in Hong Kong stock market.


Pre-IPO Triapex Laboratories - Future Performance Will Lack Stability

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Triapex Laboratories (TRIAPEX HK)

Pre-IPO Triapex Laboratories - Future Performance Will Lack Stability

TRIAPEX offers end-to-end R&D services, with fair value changes of biological assets directly impacting performance stability. The final IPO...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pre-IPO Triapex Laboratories - Future Performance Will Lack Stability

​TRIAPEX offers end-to-end R&D services, with fair value changes of biological assets directly impacting performance stability. The final IPO...

Xinyao (Criss) Wang

TRIAPEX offers end-to-end R&D services, with fair value changes of biological assets directly impacting performance stability. The final IPO...